Generative artificial intelligence for de novo protein design.

Curr Opin Struct Biol

Department of Chemical Engineering, Stanford University, 443 Via Ortega, Stanford, CA 94305, USA; Stanford Data Science, 475 Via Ortega, Stanford CA 94305, USA; Arc Institute, 3181 Porter Dr, Palo Alto, CA, USA. Electronic address:

Published: June 2024

Engineering new molecules with desirable functions and properties has the potential to extend our ability to engineer proteins beyond what nature has so far evolved. Advances in the so-called 'de novo' design problem have recently been brought forward by developments in artificial intelligence. Generative architectures, such as language models and diffusion processes, seem adept at generating novel, yet realistic proteins that display desirable properties and perform specified functions. State-of-the-art design protocols now achieve experimental success rates nearing 20%, thus widening the access to de novo designed proteins. Despite extensive progress, there are clear field-wide challenges, for example, in determining the best in silico metrics to prioritise designs for experimental testing, and in designing proteins that can undergo large conformational changes or be regulated by post-translational modifications. With an increase in the number of models being developed, this review provides a framework to understand how these tools fit into the overall process of de novo protein design. Throughout, we highlight the power of incorporating biochemical knowledge to improve performance and interpretability.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sbi.2024.102794DOI Listing

Publication Analysis

Top Keywords

artificial intelligence
8
novo protein
8
protein design
8
generative artificial
4
intelligence novo
4
design
4
design engineering
4
engineering molecules
4
molecules desirable
4
desirable functions
4

Similar Publications

Early Versus Delayed Antihypertensive Treatment After Acute Ischemic Stroke by Hypertension History.

Stroke

January 2025

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. (X.X., X.L., Y.P., Yufei Wei, Y.J., M.W., J.J., X.M., Yilong Wang, Yongjun Wang, L.L.).

Background: We performed a prespecified subgroup analysis of the CATIS-2 trial (China Antihypertensive Trial in Acute Ischemic Stroke II) to compare the effect of early versus delayed antihypertensive treatment on death and disability in patients with and without medical history of hypertension.

Methods: CATIS-2 is a multicenter randomized clinical trial conducted in 106 hospitals in China. The trial randomized 4810 patients with acute ischemic stroke within 24 to 48 hours of symptom onset and elevated systolic blood pressure between 140 and <220 mm Hg to receive antihypertensive treatment immediately after randomization or to discontinue antihypertensive medications for 7 days and then receive treatment on day 8.

View Article and Find Full Text PDF

Severity of metabolic derangement predicts survival after out-of-hospital cardiac arrest and the likelihood of benefiting from extracorporeal life support.

Emergencias

December 2024

Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seúl, República de Corea. Department of Digital Health, SAIHST, Sungkyunkwan University, Seúl, República de Corea.

Objective: To develop a Metabolic Derangement Score (MDS) based on parameters available after initial testing and assess the score's ability to predict survival after out-of hospital cardiac arrest (OHCA) and the likely usefulness of extracorporeal life support (ECLS).

Methods: A total of 5100 cases in the Korean Cardiac Arrest Research Consortium registry were included. Patients' mean age was 67 years, and 69% were men.

View Article and Find Full Text PDF

Background: Diabetic kidney disease (DKD) is one of the typical complications of type 2 diabetes (T2D), with approximately 10 % of DKD patients experiencing a Rapid decline (RD) in kidney function. RD leads to an increased risk of poor outcomes such as the need for dialysis. Albuminuria is a known kidney damage biomarker for DKD, yet RD cases do not always show changes in albuminuria, and the exact mechanism of RD remains unclear.

View Article and Find Full Text PDF

Developing Mobile Health Applications for Inflammatory Bowel Disease: A Systematic Review of Features and Technologies.

Middle East J Dig Dis

October 2024

Department of Health Information Technology, Ferdows Faculty of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran.

Background: Patients with inflammatory bowel disease (IBD) require lifelong treatment, which significantly impacts their quality of life. Self-management of this disease is an effective factor in managing chronic conditions and improving patients' quality of life. The use of mobile applications is a novel approach to providing self-management models and healthcare services for patients with IBD.

View Article and Find Full Text PDF

KSA is transforming its healthcare system by developing and implementing Clinical Practice Guidelines (CPGs), a tool designed to improve patient outcomes, standardize care, and facilitate evidence-based decision-making. CPGs are crucial in addressing healthcare disparities, thereby promoting health equity and patient experience. They are integral to KSA's healthcare transformation agenda.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!